E-Therapeutics PLC
LSE:ETX
E-Therapeutics PLC
LSE:ETX
Price:
9.4 GBX
-3.59%
Market Closed
Updated:
May 4, 2024
E-Therapeutics PLC
Cash from Financing Activities
|
E-Therapeutics PLC
Cash from Financing Activities Peer Comparison
Comparables:
CNTA
AUTL
BCYC
IMCR
GNS
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
E-Therapeutics PLC
LSE:ETX
|
Cash from Financing Activities
£13m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
305%
|
CAGR 10-Years
91%
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Cash from Financing Activities
$21.1m
|
CAGR 3-Years
149%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Cash from Financing Activities
-$883k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Cash from Financing Activities
$250m
|
CAGR 3-Years
22%
|
CAGR 5-Years
58%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Cash from Financing Activities
£34.3m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
221%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Cash from Financing Activities
-£20.5m
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is E-Therapeutics PLC's Cash from Financing Activities?
Cash from Financing Activities
13m
GBP
13m
GBP
Based on the financial report for Jan 31, 2023, E-Therapeutics PLC's Cash from Financing Activities amounts to 13m GBP.
What is E-Therapeutics PLC's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
91%
91%
Over the last year, the Cash from Financing Activities growth was -42%.
You don't have any saved screeners yet
